Cardiovascular disease, CVD, is a complex disease driven by multiple genes and pathways. As the leading cause of deaths globally, CVD results in an estimated 17.9 million deaths each year. The current standards of care treatments are unable to target the underlying etiology of CVD to reverse the course of cardiac degeneration, creating an unmet medical need for novel regenerative therapies that target its multifaceted aspects.
Multigenic gene and cell therapies are engineered as a single therapy to target multiple disease-associated genes, pathways, or processes, which are the hallmarks of complex and severe diseases. BeatBio is pursuing the development of multi-modal multigenic therapies to target such diverse causes of CVD. The modalities include multi-effector pDNA therapy, exosome therapy, and gene-modified mesenchymal stem cell therapy.
BeatBio will deploy its parent company BioSolution Designs (BSD) proprietary multigenic technology platforms to design, control and deliver its multigenic therapies. BSD’s multigene vector design and control technology enable intuitive assembly of complex multigene vectors and BSDs gene delivery technologies have the potential to simplify delivery of large genetic payloads to cells and tissues.
Founder, CEO & Chairman
Dr. Thomas Reed, is the leading force and authority on harnessing the power of DNA for a broad range of applications. He was the Founder and 20+ year Chief Science Officer of Intrexon, and was the Co-Founder of Triple-Gene, a cardiovascular disease subsidiary of Intrexon.
Chief Development Officer
Shruti Abbato is a corporate development leader. She was chief business executive at SalioGen and at MaxCyte, responsible for division building and fundraising activities. Over her 20+ year career, she has led numerous strategy and deal processes for early-stage and publicly traded companies.
Chief Operations Officer
Sam Glickstein brings diverse experience to his role as Chief Operating Officer, backed by 10+ years focused on operations and strategic initiatives. His career spans leadership roles within the bioindustry including Founder and CEO of BioTrophics, a novel insect genetic engineering company.
Lead Scientific Advisor
Dr. Litsa Kranias is the Hanna Professor and Director of Cardiovascular Biology at the University of Cincinnati College of Medicine. She is a rare researcher who has successfully traversed the “bench to bedside” drug discovery-to-drug development path. Dr. Kranias holds a PhD in Molecular Biology and Biochemistry
Lead Scientific Advisor
Dr. Litsa Kranias is the Hanna Professor and Director of Cardiovascular Biology at the University of Cincinnati College of Medicine. She is a rare researcher who has successfully traversed the “bench to bedside” drug discovery-to-drug development path. Dr. Kranias holds a PhD in Molecular Biology and Biochemistry and a Masters in Biology from Northwestern University, and a Bachelors in Biology/Biochemistry from University of Chicago.
Lead Medical Advisor
Amit Patel, M.D., is a cardiac surgeon and former Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah in Salt Lake City. He was a tenured professor of surgery-cardiothoracic at the University of Utah until December 2016. Dr. Patel studied medicine at Case Western Reserve Univers
Lead Medical Advisor
Amit Patel, M.D., is a cardiac surgeon and former Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah in Salt Lake City. He was a tenured professor of surgery-cardiothoracic at the University of Utah until December 2016. Dr. Patel studied medicine at Case Western Reserve University, holds a Masters in Immunophysiology, and a Bachelors in Biological Sciences from Youngstown State University.
Business Advisor
Cena Hillard is Associate Dean of Finance, Administration & Business Operations of the Case School of Engineering. She makes recommendations on policy development and strategy and is responsible for business planning. Ms. Hillard holds an MBA from Case Western Reserve University, a Masters in Cell and Molecular Biology fr
Business Advisor
Cena Hillard is Associate Dean of Finance, Administration & Business Operations of the Case School of Engineering. She makes recommendations on policy development and strategy and is responsible for business planning. Ms. Hillard holds an MBA from Case Western Reserve University, a Masters in Cell and Molecular Biology from University of Wisconsin -Madison, and a Bachelors in Biology from Carnegie Mellon University.
Business Advisor
Eric Anderson was formerly Co-founder, President, and Managing Director of GAJE Healthcare Consulting, Inc, a firm specializing in brand development and marketing for the pharmaceutical and biopharmaceutical markets. Prior to this he was at Bayer Corporation’s Pharmaceutical Division as Director of Trade DevelopmentMr. A
Business Advisor
Eric Anderson was formerly Co-founder, President, and Managing Director of GAJE Healthcare Consulting, Inc, a firm specializing in brand development and marketing for the pharmaceutical and biopharmaceutical markets. Prior to this he was at Bayer Corporation’s Pharmaceutical Division as Director of Trade DevelopmentMr. Anderson holds an MBA from the University of New Haven and a Bachelors in Pharmacy from the Philadelphia College of Pharmacy and Science.
Founder, CEO & Chairman
Dr. Reed, is the leading force and authority on harnessing the power of DNA for a broad range of applications. He was the Founder and 20+ year Chief Science Officer of Intrexon, and was the Co-Founder of Triple-Gene, a cardiovascular disease subsidiary of Intrexon. He earned his PhD in Molecular and Developmental
Founder, CEO & Chairman
Dr. Reed, is the leading force and authority on harnessing the power of DNA for a broad range of applications. He was the Founder and 20+ year Chief Science Officer of Intrexon, and was the Co-Founder of Triple-Gene, a cardiovascular disease subsidiary of Intrexon. He earned his PhD in Molecular and Developmental Biology from the University of Cincinnati College of Medicine. He holds a Masters in Biological Sciences from Wright State University and a Bachelors in Genetics from the University of California, Davis.
Director
Ryan Barrett is SVP, General Counsel, and Lead of Corporate Development for ATAI Life Sciences. Over the course of his career, Ryan has held multiple strategic and operational roles within various biotechnology, not-for-profit and financial services companies. Ryan is an attorney admitted to the bar of the Commonwealth of Massach
Director
Ryan Barrett is SVP, General Counsel, and Lead of Corporate Development for ATAI Life Sciences. Over the course of his career, Ryan has held multiple strategic and operational roles within various biotechnology, not-for-profit and financial services companies. Ryan is an attorney admitted to the bar of the Commonwealth of Massachusetts; he holds a B.S. in biochemistry and a B.A. in Italian language from Trinity College (Hartford, CT), and a J.D. from Case Western Reserve University School of Law (Cleveland, OH).
BioSolution Designs Announces Formation of BeatBio Subsidiary to Develop Complex Multigenic Cardiovascular Therapies.
BeatBio Appoints Ryan Barrett, a Seasoned Life Sciences Executive, to the Company's Board of Directors.
BeatBio Expands Multi-Disciplinary Advisory Team, Adding Three Experts in the Fields of Medicine, Financial Operations, and Pharmaceutical Marketing.
1776 Mentor Avenue, Cincinnati, OH 45212
Copyright © 2024 BeatBio - All Rights Reserved.